You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.


Cancer Type: Hematologic, Multiple Myeloma      Intent: Palliative
Regimen Category: Evidence-Informed
New Drug Funding Program
    Daratumumab – In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
Exceptional Access Program
    lenalidomide - In combination with daratumumab and dexamethasone for the treatment of relapsed multiple myeloma, with specific criteria

You might also be interested in